Navigation Links
New hope in the fight against childhood cancer
Date:7/11/2013

Researchers in the Antibody and Vaccine Group have developed two monoclonal antibodies (mAbs) called anti-4-1BB and anti-CD40 and investigated a third called anti-CTLA-4. Each of these antibodies binds to a different target molecule in the immune system, potentially heightening the body's own immune response to cancer.

Published in the July edition of Clinical Cancer Research, the study has shown that the antibodies boost the immune system to fight neuroblastoma -- a form of childhood cancer which grows from undeveloped tissue of the nervous system.

They found that 40 to 60 percent of the tumours treated with the stimulatory antibodies regressed in the laboratory models and ensured long-term survival. With more aggressive tumours, the antibodies alone did not significantly slow tumour growth, however, when the researchers paired one of the monoclonal antibodies with a cancer vaccine called Survivin a similar survival benefit was seen.

Dr Juliet Gray, Senior Lecturer in Paediatric Oncology and Cancer Research UK scientist at the University of Southampton, comments: "Although this work is still at a pre-clinical stage, we hope it has enabled us to identify a way that we can provide effective immunotherapy treatment against neuroblastoma. More research is needed to understand how these antibodies work and how they should be used to treat neuroblastoma.

"Six out of ten children with neuroblastoma can be successfully treated with conventional chemotherapy. But for those children who don't respond well to this treatment, immunotherapy could become a vital new treatment option."

The body's immune response is generally much weaker to cancer than it is to infections, and in most cases it does not stop tumours from growing. The body holds anti-cancer cells called T-cells, but cancer has the ability to switch off or subdue the immune recognition in these cells.

The antibodies are engineered to wake the T-cells up from their slumber and thereby restore the anti-cancer activity to attack the tumour. This process is already being used in adult trials for a range of cancers including skin, head and neck and pancreatic cancer. This pre-clinical data will allow Dr Gray and her team to design the first peadiatric clinical trials.

Dr Gray, who is also a paediatric oncologist at Southampton General Hospital, adds: "Neuroblastoma affects around 100 children in the UK each year with most cases being diagnosed under the age of five. It is a serious disease but we need to be clear about how to move forward with it. There are a number of things that make conducting a clinical trial in children very challenging. Therefore, it is important that we learn as much as we can in the lab, in advance of a clinical trial, about how this type of therapy can be best used in childhood cancers."

Cancer Research UK scientist, Professor Martin Glennie, Head of the Cancer Sciences at the University of Southampton, who also worked on the study, says: "We very much hope these results will enable us to develop a pioneering immunotherapy treatment for a childhood cancer. In theory this approach enables us to kill cancer cells without damaging healthy cells, resulting in fewer toxic side effects such as hair loss, nausea and tiredness.

"The next stage of our work will be to see if the treatment is a safe and effective treatment for children and also seek to understand how these antibodies can be used in combination with other treatments to maximise their effect."


'/>"/>

Contact: Becky Attwood
r.attwood@soton.ac.uk
44-023-805-95457
University of Southampton
Source:Eurekalert

Related medicine news :

1. Eliminating the good cholesterol receptor may fight breast cancer
2. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
3. From a Failed Vaccine, New Insights Into Fighting HIV
4. Doctors Detail High Costs of Fighting Malpractice Claims
5. How does the immune system fight off threats to the brain? New research yields fresh insight
6. Exercise Can Help Fight Heart Failure
7. Scripps Research scientists show how memory B cells stay in class to fight different infections
8. Southeast program to fight diabetes awarded nearly $10 million by HHS
9. Soybeans soaked in warm water naturally release key cancer-fighting substance
10. Living longer - variability in infection-fighting genes can be a boon for male survival
11. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... announce that their Vice President of Franchise Development, Paula Turner Pizarro, was recently ... business program, which features the insights of top business leaders from across the ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that Mr. Michael ... the upcoming WCBP Conference, to be held at the Mayflower Hotel, Washington DC, ...
(Date:1/18/2017)... ... ... Floundering on New Year’s resolutions? Need an excuse to get back on ... U.S. Apple Association agrees and recommends starting each day with apples, a habit ... disease. , The U.S. Apple Association – which represents apple growers and producers nationwide ...
(Date:1/17/2017)... ... ... For breast cancer clinicians and researchers who were unable to attend the ... review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual Best ... February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO from ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate ... Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center ... been the gold standard for high-definition, in-ear earphones. This classic earphone has been ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
(Date:1/18/2017)... enero de 2017  Hoy, en el Foro Económico ... iniciativa global para avanzar el acceso a la prevención ... de renta baja y baja-media (LICs y LMICs). ... crisis, particularmente en países de renta baja y media, ... las muertes relacionadas con NCD. El objetivo de Access ...
(Date:1/18/2017)... -- With an annual growth ranging from 6% to 10%, South East Asia,s ... Expo, March 22-24, 2017) serves the industry by fostering the regional discourse - ... Investment Forum ASEAN -- India ... content Enhanced business matchmaking program Roadshows ... ...
Breaking Medicine Technology: